tiprankstipranks
CytomX Therapeutics price target lowered to $2 from $4 at Mizuho
The Fly

CytomX Therapeutics price target lowered to $2 from $4 at Mizuho

Mizuho analyst Mara Goldstein lowered the firm’s price target on CytomX Therapeutics (CTMX) to $2 from $4 and keeps a Neutral rating on the shares. The company’s Q4 report included AbbVie’s (ABBV) decision to decline advancing CX-2029, leaving CytomX with an option to re-acquire rights, the analyst tells investors in a research note. CytomX has indicated this is under consideration, but the new price target reflects its removal, says the firm.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CTMX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles